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Total parenteral nutrition (TPN), or the complete absence of enteral nutrients, is com-
monly used in a clinical setting. However, a major consequence of TPN administration is
the development of mucosal atrophy and a loss of epithelial barrier function (EBF); and
this loss may lead to an increase in clinical infections and septicemia. Our laboratory has
investigated the mechanism of this TPN-associated loss of EBF using a mouse model.
We have demonstrated that the mucosal lymphoid population significantly changes
with TPN, and leads to a rise in interferon gamma (IFN-γ) and decline in interleukin-10
(IL-10) expression—both of which contribute to the loss of EBF. Associated with these
cytokine changes is a dramatic decline in the expression of tight junction and adherens
junction proteins. This article discusses the potential mechanisms responsible for these
changes, and potential strategies to alleviate this loss in EBF.
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Introduction
The intestinal epithelium undergoes both
morphological and functional changes dur-
ing total parenteral nutrition (TPN) admin-
istration. Many patients, because of either
gastrointestinal dysfunction or a lack of intesti-
nal length, are unable to tolerate enteral feed-
ings. These patients are confined to a prolonged
course of TPN. It is estimated that over 250,000
patients receive TPN in the United States alone
on a yearly basis,1 resulting in over 11.5 million
patient days of care per year. Increasingly, inves-
tigators have found that the intestine undergoes
significant changes during the administration
of TPN with an absence of enteral nutrition.
In several TPN animal models, the intestinal
epithelium shows a loss of villus height and a
decline in epithelial growth.2,3 Further analysis
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of the mucosa shows a loss of epithelial bar-
rier function (EBF) during the administration
of TPN.4 This loss of barrier function may re-
sult in endotoxins and even bacteria entering
the systemic circulation.
Clinical Consequences
of a Loss of Epithelial Barrier
Function with TPN
Loss of EBF with TPN may well be a poten-
tial mechanism for the observed higher rates
of septicemia and other clinical infectious pro-
cesses. Significantly higher rates of sepsis and
infection have been strongly associated with
TPN in the clinical settings of surgery and
trauma.5,6 The etiology of these increased rates
of infection is controversial. Systemic immuno-
logic changes are quite common during the
administration of TPN, and include both a
decrease in absolute lymphocyte counts and a
depression in lymphocyte function.7–9
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Use of a TPN Mouse Model to
Study Mucosal Atrophy and
Epithelial Barrier Function
The mouse model of TPN has yielded valu-
able insights and may actually more closely re-
semble clinical TPN administration than other
animal models. Previous studies with TPN in
rat models showed a rapid progression of vil-
lus atrophy within a matter of 3 days.10 Such
changes do not occur as rapidly in humans re-
ceiving TPN, and thus must be carefully inter-
preted. Mouse models of TPN show the devel-
opment of villus atrophy and formation of an
epithelial barrier leak in a delayed period of
onset (twice as long as rats), and more similar
(although still more rapid) to humans.
TPN Administration Results in a Loss of
Mucosal Barrier Function
Loss of EBF has been identified both in ex-
perimental models of TPN3,10,11 and in hu-
mans.12 The mechanism by which TPN leads
to a loss of epithelial integrity has only re-
cently been approached. In vitro cultures of in-
testinal epithelial cells (EC) have given critical
insight into these mechanisms. A number of
cytokines influence EBF. This was first shown
in human intestinal EC (T84 cell line) incu-
bated with interferon gamma (IFN-γ).13 Using
a similar in vitro model, others have shown that
pretreatment with transforming growth factor
beta 1 (TGF-β1) can prevent the effects of IFN-
γ.14 A number of other cytokines have also
been shown to affect EBF. Similar to TGF-
β1, interleukin-10 (IL-10) can attenuate the loss
of epithelial barrier in T84 monolayers caused
by IFN-γ.15 Interleukin-4 (IL-4), however, can
lead to a loss of EBF in a similar in vitro model.16
Other cytokines which have been associated
with a loss of EBF include interleukin-6 (IL-
6) and tumor necrosis factor alpha (TNF-α).17
Loss of barrier function with TPN appears to
be closely associated with the increased expres-
sion of IFN-γ by intraepithelial lymphocytes
(IEL).11,18
Gut-Associated Lymphoid Tissue
The gastrointestinal tract is exposed to a
number of foreign antigens on a daily ba-
sis, including toxins, bacteria, viruses and a
number of diverse enteral nutrients. A critical
part of protecting the host from these factors
is the gut-associated lymphoid tissue (GALT).
The GALT is a complex immunologic organ
that contains several layers within the intesti-
nal tract.19–21 The layer of the GALT closest to
the lumen is the IEL. The IEL has a unique
T-cell phenotype and plays a critical role in
both proliferative and cytotoxic T-lymphocyte
actions.22,23 The IEL phenotype predomi-
nately consists of CD4−,CD8+ (70–85%, for
mice, single positive), with other less frequent
subpopulations: CD4−,CD8− (5–10%, double
negative); CD4+,CD8− (5–12%, single posi-
tive); and CD4+,CD8+ (4–10%, double posi-
tive).24,25 The IEL also has a large number of
γδ-TCR+ cells (30–70%, compared to less than
2% in peripheral blood lymphocytes of mice).26
The IEL is thought to be derived from both a
thymic-dependent and a thymic-independent
source. Although still controversial,27 studies
suggest that the IEL originate from both the
intestinal tract and the thymus.27,28 RAG2−/−
mice injected with bone marrow of nude mice
failed to develop peripheral T-cells but did de-
velop a nearly normal IEL population, which
contained CD8+ T-cells with both γδ- or αβ-
TCR+ phenotype.29 Although still controver-
sial, the thymic-independent portion of the IEL
is best defined by the CD8αα (homodimeric)
T-cell population. In contrast, CD8αβ (het-
erodimeric) cells are believed to be of thymic
origin. The function of the IEL has not been
completely determined. Using a redirected cy-
totoxic functional assay without in vitro activa-
tion, the IEL shows considerable activity.30 The
actual significance of these actions has not been
completely defined but suggests a role in pro-
tecting the organism from harmful intralumi-
nal pathogens. The IEL is also a rich source
of cytokines, including: IFN-γ,31 IL-2,32 IL-
4,33 IL-6,34 TNF-α,35 and TGF-β1.36 TGF-β1
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has been detected in both αβ-TCR+ and γδ-
TCR+ IEL subsets.37 IL-10 has recently been
shown to be expressed in the IEL, and may
closely relate to the modulation and function
of T-regulatory cells.38 Cytokine production in
the αβ-TCR+ fraction of the IEL has been ex-
tensively studied, and the CD4+,CD8− pop-
ulation expresses IFN-γ, IL-4 and IL-5.37,39
The CD4+,CD8+ population expresses greater
amounts of IFN-γ and IL-5. The CD4−,CD8+
population produces IFN-γ, IL-5 and some
IL-6. It appears that a major aspect of IEL
regulatory function is achieved by specific cy-
tokine production. It is hypothesized that IEL
cytokine production leads to modulation in ep-
ithelial cell function,40 as well as to a downreg-
ulation of immunologic sensitization to foreign
antigen.33
Intraepithelial Lymphocytes
Closely Interact with Mucosal
Epithelial Cells
Because of the close physical association of
the IEL with mucosal EC, interactions between
the two populations have been examined. EC
express essential ligands which are needed for
IEL to adhere and reside within the mucosal
epithelium.41 Interestingly, these ligands are ex-
pressed along the basolateral surface of the EC,
in juxtaposition to IEL. Perhaps the best char-
acterized of these is the integrin αEβ7 on the
IEL and E-cadherin on the surface of the ep-
ithelial cells.42 Another important manner in
which the IEL and EC intercommunicate is
via the large number of cytokines, growth fac-
tors and chemokines which are expressed by
EC. One such example is that EC-derived IL-
7 strongly influences the development, growth
and phenotype of the adjacent IEL.43 IL-7−/−
or IL-7R−/− mice show distinct declines in ab-
solute numbers of thymocytes and IEL, with a
virtual absence of the γδ-TCR+ population,
and fewer αβ-TCR+ T cells than wild-type
mice.44
Changes in the Intraepithelial
Lymphocytes with Total Parenteral
Nutrition Administration
Phenotypic Changes
A number of IEL phenotypic alterations oc-
cur with TPN, and include a marked decline in
the CD4+, CD44+, and CD8αβ+ populations
(Table 1). The CD4+ population is known to be
very responsive to exogenous stimulation, and
its loss may explain an observed loss of IEL
proliferative responsiveness with TPN.31 The
loss of the CD8αβ+ population with TPN may
represent a loss of the thymic-dependent pop-
ulation of the IEL,29 and the loss of CD44+
cells suggests a shift to a less mature IEL.45 In-
terestingly, the alteration in IEL phenotype did
not correlate with enteral anaerobic or aerobic
bacterial cultures, in that the number and strain
of these bacteria did not significantly change
with TPN.31 An additional group is shown in
Table 1—that of TPN mice allowed small
amounts of enteral food (TPN + Food group;
comprising 25% of caloric needs). Interestingly,
IEL phenotype changes were significantly in-
fluenced by the loss of enteral nutrition; most
of the observed IEL changes with TPN were
reversed with the addition of this small amount
of enteral nutrition. The mechanism by which
enteral food prevents the observed IEL changes
has not been determined.
Cytokine Expression
Table 2 shows changes in cytokine expression
with TPN.31,36,46 This panel of cytokines was
chosen because each of these has been shown
to alter either barrier function or apoptotic sig-
naling in the intestine.15,16,47–51 Our labora-
tory reported a rise in IFN-γ expression with
TPN, and this could well impact both the ob-
served increase of EC apoptosis52 and a loss of
EBF (see below). In addition to IFN-γ, other
cytokines may also have relevance to EC physi-
ology, including IL-4, IL-6 and IL-10 (Table 2).
As mentioned above, each of these cytokines
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TABLE 1. Small Bowel IEL Phenotype in Control and TPN Mice
IEL Phenotypes Description Control (range) TPN (range) TPN + Food (range)
CD4 and CD8α
CD4+CD8− single positive 4.7 (3.9–6.1) 0.6 (0.2–0.7)
∗
2.5 (1.9–2.8)
CD4+CD8+ double positive 2.8 (2.5–4.3) 0.6 (0.1–1)
∗
5.4 (3.8–12.1)
CD4−CD8− double negative 28 (23–34) 35 (19–64) 16 (12–28)
CD4−CD8+ single positive 65 (58–70) 64 (37–79) 72 (67–77)
CD8αα and CD8αβ
CD8αα+ thymic-independent 64 (59–71) 52 (40–63) 72 (66–78)




TCR-αβ+ T-cell receptor 39 (33–43) 22 (21–31) 24 (18–28)
TCR-γδ+ T-cell receptor 62 (53–68) 70 (57–76) 57 (51–62)
CD44 T-cell maturity
CD8+,CD44+ 29 (28–37) 10 (1.0–18)
∗
40 (38–46)
Column on right are mice maintained on TPN and allowed 25% of their nutritional intake via the enteral route.
Results are from flow cytometry studies after gating on the IEL population. CD4,CD44 results not shown because of
the marked loss of the CD4+ population with TPN. Results are expressed as mean% gated IEL (ranges) and represents
an N = 6 mice for each group. ∗ P < 0.01, by ANOVA.
TABLE 2. mRNA Expression of IEL Cytokines in Control, TPN and TPN + Food Groups
Groups IL-4 IL-6 IL-10 IFN-γ
Control 0.10 ± 0.1 0.02 ± 0.0 0.55 ± 0.2 0.15 ± 0.1
TPN 0.73 ± 0.3∗ ∗ 0.95 ± 0.3∗ ∗ 0.23 ± 0.1∗ ∗ 0.29 ± 0.1∗
TPN + Food 0.11 ± 0.1 0.05 ± 0.0 0.65 ± 0.2 0.14 ± 0.0
Note the significant alterations in all measured cytokines with administration of TPN, and the prevention of these
changes with the addition of enteral feedings to TPN mice. N = 6, ∗ P < 0.05, ∗∗P < 0.01 TPN versus Control and
TPN + Food; using ANOVA. In general, a Bonferonni post hoc t test is used for remaining preliminary results. Results
are the mean (±SD) mRNA expression of cytokine from purified IEL (via magnetic beads) samples, and expressed as
the ratio of cytokine expression to beta actin. (Ref. 55)
can contribute to changes in EBF. It is possi-
ble that the decline in IL-10 mRNA expres-
sion and the rise in IL-4 and IL-6 may all
contribute to the development of the TPN-
associated epithelial leak and increased rates
in EC apoptosis. The administration of 25%
enteral nutrition to TPN mice prevented these
cytokine changes. As mentioned earlier, EC-
derived IL-7 is another important cytokine
within the intestinal mucosa. Our laboratory
has shown a close physical relation between EC
that express IL-7 and IEL.53 Subsequently, we
showed that the administration of TPN results
in a significant decline in IL-7 expression.54
With the administration of exogenous IL-7,
much of the IEL phenotypic changes associated
with TPN can be prevented,54 suggesting that
IL-7 may have an important role in the media-
tion of the changes to the mucosa with TPN
administration. Based on these observations,
our group developed a transgenic mouse with
intestinal epithelial cell overexpression of IL-7.
These mice failed to undergo the loss of IEL




and Epithelial Barrier Function
TPN-associated increases in IEL-derived
IFN-γ and decline in IL-10 expression have
both been associated with a loss of EBF.11,18,57
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Figure 1. Transepithelial resistance (TER) in mice
was measured in Ussing chambers after a 30-minute
equilibration period. Results (mean ± SD) in six
mice per group. TPN significantly decreased in-
testinal TER in wild-type mice. Elimination of IFN-γ
was achieved using knockout mice (IFNKO). Signif-
icance was found between the TPN and all other
study groups; the other groups were not signifi-
cantly different among themselves. ANOVA was used
for statistical analysis. ∗P < 0.05 comparing TPN
group to other groups, with a Bonferonni post hoc
analysis.
A significant decline in transepithelial resis-
tance (TER) of full-thickness ileum is noted
in the TPN group. In order to determine the
influence that increased expression of IFN-γ
had on this change in EBF, a series of IFN-γ
knockout mice underwent TPN administra-
tion. In the absence of IFN-γ, the degree of
TPN-associated epithelial barrier breakdown,
as measured by either the permeability coef-
ficient (Papp) or by transepithelial resistance
(TER) (Fig. 1), was significantly lessened.46 The
fact that permeability levels did not completely
return to normal suggested that other media-
tors of this breakdown exist. Whether this is a
direct action of IFN-γ on the EBF, or if acts to
prime tumor necrosis factor receptors remains
to be determined.58 Subsequently, our group
then determined the influence of the decline
in IL-10 with TPN administration. Sun et al.
demonstrated that the additional administra-
tion of exogenous IL-10 to mice receiving TPN
resulted in a return of EBF toward normal.57
Similar to the IFN-γ mice, exogenous IL-10
partially prevented this barrier loss; however,
the effect was only about 50% effective. This
Figure 2. Immunofluorescent images of represen-
tative portions of mid-small bowel mucosa in control
(enterally fed) and TPN study groups. Note the loss of
junctional and adherens proteins with TPN. Addition-
ally, note the movement of some of these proteins (oc-
cludens) into the cytoplasm with TPN administration.
suggests that the cytokine changes with TPN
administration account for a substantial degree
of EBF loss.
Alteration in the Tight Junction
with Total Parenteral Nutrition
The etiology of this loss of EBF was further
investigated. Our laboratory detected a sub-
stantial decline in the expression of a number
of tight junction molecules,57 including ZO-1,
occluden, several claudins and JAM-1, as well
as the adherens molecule E-cadherin. Figure 2
shows immunofluorescent images of some of
these factors. In addition to a loss of expres-
sion, internalization (endocytosis) of some of
these factors can be seen—a finding similarly
observed in vitro with cytokine exposure to ep-
ithelial monolayers, as well as other clinical dis-
ease processes where EBF is lost, such as in
inflammatory bowel disease.50,59,60
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Figure 3. Effect of TPN on the permeability co-
efficient (Papp) of tritiated mannitol as measure in
Ussing chambers of full-thickness ileal specimens with
TPN administration (∗P < 0.05). Note also the return
of permeability to control levels when TPN mice are
given exogenous keratinocyte growth factor (KGF)
(5 mg/kg/day).64
Therapeutic Options to Prevent
Barrier Loss with Total Parenteral
Nutrition
The IEL not only expresses a number of
cytokines, but the γδ-TCR subpopulation has
been shown to express keratinocyte growth
factor (KGF, or fibroblast growth factor-7).61
Our group has subsequently demonstrated that
with TPN administration, there is a marked
decline in KGF expression by this IEL sub-
population.62 Further, the exogenous admin-
istration of KGF to mice receiving TPN was
able to significantly prevent loss of villus height,
crypt depth, and restored EBF (Fig. 3).63 This
suggests that the use of KGF may have a thera-
peutic potential for patients on long-term TPN
and may prevent many of the complications
associated with EBF loss.
Conclusions
TPN results in a loss of villus height, loss of
EC proliferation, rise in EC apoptosis, and a
marked decline in EBF. Using a mouse model
of TPN, the IEL has been shown to undergo
significant changes. Such changes may partially
account for the mechanism of EBF loss with
TPN, and may contribute to the increased in-
cidence of septicemia with TPN administra-
tion. The mechanisms by which IEL change
with TPN are not known, but data suggests
that such changes are due to a lack of enteral
nutrition and may be mediated by a decline
in EC-derived IL-7. Understanding the mech-
anisms that are responsible for such changes
may lead to the potential for therapeutic op-
tions in patients receiving TPN. Further, un-
derstanding the changes in the IEL with TPN
administration may also yield important infor-
mation in how EC-IEL interactions take place.
Such interactions appear to directly influence
observed alterations in the physiology of the
intestinal mucosa. Thus, these cell-cell interac-
tions may have important applications in other
processes, such as gut adaptation after bowel re-
section, or during autoimmune processes, such
as inflammatory bowel disease.
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